CDCaio Vitor Bueno Dias

Caio Vitor Bueno Dias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caio Vitor Bueno Dias has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Laboratory changes inherent to acute kidney injury induced by aminoglycosides in wistar rats

    by Ana Carolina Queiroz Lima, Ana Bárbara Freitas Rodrigues Godinho, Caio Vitor Bueno Dias, Vinícius Novaes Rocha, Hassan Jerdy

    Acute kidney injury (AKI) is defined as an increase greater than 0.3 mg/L of serum creatinine within 48 hours and is a major cause of death in patients in intensive care units. Twenty-four Wistar rats were divided into three groups: Control (0.9% saline), Genta (gentamicin 50 mg.kg-1 BID) and Deh+Genta (gentamicin 50 mg.kg-1 BID + water restriction) and tested in an AKI model by aminoglycoside administration and dehydration implementation. The animals in the Deh+Genta group exhibited the lowest average weight and feed intake after the fifth day of the experiment. In this same period, water consumption by the Genta group was lower than the Control group, but in the following days of the experiment, polydipsia was noted for this group. The Deh+Genta group displayed the highest mean serum urea after the fifth day. The gentamicin-treated groups exhibited higher means than the Control group for serum creatinine, which proved to be a late renal marker for AKI. Serum GGT was higher in the Deh+Genta group, whereas urinary GGT was higher in the groups that received gentamicin, characterizing enzymuria, although severe dehydration can mask the results by indicating false negative values. The urinary GGT enzyme did not act as an early AKI biomarker. Decreased glomerular filtration rates enhanced the concentration of blood components and masked urinary and tissue components.

  • Protocolos terapêuticos para cães com hemangiosarcoma esplênico – revisão sistemática

    by Centro Universitário Luterano de Palmas, Bárbara Rocha Pereira, Caio Vitor Bueno Dias, Ana Luiza Silva Guimarães

    Hemangiosarcoma is a malignant and aggressive tumor composed of pleomorphic endothelial cells filled with blood and solid cell agglomerations. This tumor has a larger sample in dogs, especially the elderly aged 8 to 13 years. The aim of this systematic review is to understand and evaluate therapeutic protocols for dogs with splenic hemangiosarcoma. To this end, articles published from 2010 to 2020 were searched in the PubMed database, covering national and international publications. In total, 7 references were selected by the established criteria. The results of this literature review report that the clinical stage is strongly associated with the survival time of dogs with splenic hemangiosarcoma. Chemotherapy treatment is effective in increasing survival time during the early stage of the disease follow-up period. Combinations of conventional protocols containing doxorubicin and metronomic protocols containing cyclophosphamide were performed to have the greatest efficacy, but prolongations in survival time were modest. Future research should target specific protocols for animals with specific comorbidities and so far no studies have been registered that distinguish a treatment for males and females with splenic hemangiosarcoma.